USP44 Stabilizes MAOB via Deubiquitination to Inhibit Cisplatin Resistance in Lung Adenocarcinoma
<h4>Background</h4>Cisplatin (DDP), as a commonly used chemotherapeutic agent for the clinical treatment of lung adenocarcinoma (LUAD), serves a key function in suppressing tumor progression; however, the development of tumor cell resistance has restricted its clinical …
Read PDF